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Abstract With regard to the principles established for
neonatal population screening, the question arises whe-
ther for patients with urea cycle disorders there is an
accepted treatment which really aﬀects the disease
course and prognosis as compared to the natural history
of these diseases. A retrospective study of 88 patients
was performed. Based on questionnaires, the survival
rate and neurodevelopmental outcome of patients trea-
ted with protein restriction alone was compared to the
new therapy introduced in the 1980s with added citrul-
line/arginine, essential amino acids for improving the
amino acid composition of the restricted natural protein
and benzoate. Survival of patients with neonatal pre-
sentation was improved by the extensive therapy but this
mostly at the cost of an increasing number of retarded
patients. Long-term outcome did not diﬀer signiﬁcantly
between the two treatments. Of all patients, 56% were
symptomatic within 4 days of age and 67% within the
1st week. Thus a prevention of irreversible damage by
neonatal screening on blood obtained at 3–4 days of life
is questionable. Whether the beneﬁt of obtaining a rapid
diagnosis, e.g. for allowing proper counselling and
prospective treatment, is acceptable for the parents of
prospective patients remains open. The organisation of a
dense network of specialised metabolic centres with
suﬃcient staﬀ and resources is a prior condition for any
screening programme in order to ensure the rapid
diagnosis, follow-up of treatment and counselling of a
cumulative number of aﬀected chronic patients needing
this support. A commitment on a long-term basis by the
institutions is needed in view of the health budget
restrictions. Conclusion: In the short term, the goal is to
detect hyperammonaemic patients as early as possible
with special emphasis on sick neonates. In practice,
quantitative plasma ammonia determination without
delay is recommended in any newborn for whom a sepsis
work-up is considered and in children who refuse feed-
ing or vomit and show alterations of consciousness and/
or neurological symptoms.
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disorder
Introduction
The opportunity of using new techniques in neonatal
screening for genetic metabolic disorders has led to
suggestions to include urea cycle disorders (UCD) in
such programmes. The success of neonatal screening for
phenylketonuria (PKU) has stimulated scientists to
adapt and develop methods for testing markers for other
metabolic disorders and start pilot programmes in order
to widen the range of analytes tested in neonatal
screening. Whilst showing the analytical feasibility, some
have assumed implicitly that other diseases fulﬁll the
same basic criteria as PKU and that feasibility is the
main hurdle for introducing new programmes. However,
past experience should be taken into account and
accepted criteria, described in (still valid!) agreements
between governments, should be respected.
Background
The conditions to be fulﬁlled by population screening
programmes had been initially phrased by Wilson and
Jungner [15] followed by practical proposals by an ex-
pert group of the WHO [3]. When in 1979 a controversy
arose concerning new disease groups, the Public Health
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Committee of the European Council updated the rec-
ommendations of 1972. This led to a report on ‘‘Neo-
natal Mass Screening for Metabolic Disorders’’ which
was adopted by the Public Health Committee (parties:
Belgium, France, Federal Republic of Germany, Italy,
Luxembourg, the Netherlands, the United Kingdom;
Austria, Denmark, Ireland and Switzerland). A short
version was published [4]. The introduction of tandem
mass spectrometric techniques into clinical laboratories
incited the British Health Technology Assessment
Groups to commission an expert group to analyse the
cost, yield and outcome in neonatal screening for inborn
errors of metabolism (including psychological and ethi-
cal issues). This analysis is an excellent summary and a
thorough and careful discussion on the many aspects of
neonatal screening [10].
Concerning the principles of early disease detection in
UCD some questions still remain unanswered:
1. Is there an accepted treatment for patients with
recognised disease which really aﬀects the disease
course and prognosis as compared to the natural
history of UCD? Are long-term side-eﬀects of treat-
ment known?1
2. Are enough facilities available for rapid diagnosis
and treatment in order to ensure adequate control
and adaptation of therapy without excessive travel
distance for the patients? Is there a commitment for
guaranteeing the resources needed (specialised know-
how and equipment) on a long-term basis?
3 Which test would be suitable for recognising all the
UCD at an early or even latent stage (very high
sensitivity, with tolerable false-positive rates)?
4. Would the screening and its consequences be
acceptable to the parents (and prospective patients)
after adequate information?
When confronted with hyperammonaemic patients
(especially neonates) who are in coma, one has to
decide either on palliative or intensive treatment and
the question of the individual prognosis arises in the
discussion with the parents. There are some data from
large centres, mostly concerning survival rates or re-
stricted to patients having survived the neonatal period
[5]. Msall et al. [9] and Uchino et al. [13] addressed the
question of neurodevelopmental handicap; but to our
knowledge there are no data comparing the outcome
of patients treated with the actual means (‘‘new ther-
apy’’) as compared to the natural history of the UCD
(‘‘old therapy’’) for testing the improvement. We
consider the ‘‘old therapy’’ with protein restriction
(and some acute interventions of low eﬃciency like
blood exchange transfusion and peritoneal dialysis) as
being close to the natural history of the UCD with
respect to long-term outcome. The ‘‘new therapy’’ with
supplements of missing urea cycle products (arginine
or citrulline), optimised nitrogen supply by combining
protein restriction with added essential amino acids
and drug-induced diversion of excess nitrogen to
alternate pathways (e.g. benzoate) has been used since
the early 1980s. By comparing the long-term outcome
of patients (not prospectively treated) with ‘‘new’’ and
‘‘old’’ therapy, we asked the following question: does
the ‘‘new’’ treatment of the symptomatic clinical con-
dition aﬀect its course and prognosis with respect to
life expectancy and more importantly in preventing
mental retardation as compared to ‘‘old therapy’’?
Whether the age at the ﬁrst symptom, at diagnosis or
whether plasma ammonia concentrations measured
during the ﬁrst work-up are of help for predicting a
normal or compromised neuro-developmental outcome
are presented elsewhere [2].
Patients and methods
A total of 134 questionnaires had been sent out to colleagues in
regional hospitals of varying size as well as to specialised metabolic
centres who had submitted samples for diagnosis or consulted us
for patients with UCD at the Clinical Chemistry Central Labora-
tory of the University Hospital of Berne between 1975 and 1986.
Out of 90 questionnaires returned, 88 contained suﬃcient infor-
mation: 44 on patients with ‘‘old’’ therapy and 44 with ‘‘new
therapy’’. The latter had been treated according to principles
summarised elsewhere [1].
The procedures followed by the various hospitals probably re-
ﬂect the reality one would face with a screening programme more
closely than data from a selected patient population of major
centres. There was no exclusion of patients who were symptomatic
as neonates or who did not survive 28 days. Further details about
the diagnoses are given elsewhere [2].
Results
Survival data are shown in Fig. 1. Survival is better in
the ‘‘new’’ therapy group up to 2–3 years of age; this is
due mainly to the newborn group on ‘‘new’’ therapy
where survival is signiﬁcantly higher than with ‘‘old’’
therapy ( P <0.045, Fischers exact test), but not there-
after.
If the surviving patients are analysed, one realises
that the rate of retarded patients is signiﬁcantly higher
with ‘‘new’’ therapy than with ‘‘old’’ therapy in the
neonatal group (P=0.0325). Age of ﬁrst symptom <28
days: ten were retarded, 5 normal out of 15 surviving
(and 13 dead) treated by ‘‘new’’ therapy, while with
‘‘old’’ therapy, the four surviving (22 dead) were normal
at outcome. For the group with symptomatic presenta-
tion after the neonatal age, the diﬀerence is not statis-
tically diﬀerent (see [2] for details).
When discussing the question of screening, the age at
which the ﬁrst symptom was noticed is relevant. As
shown in Fig. 2, 56% of all the patients were symp-
tomatic within 4 days of age and 67% within the 1st
week.
1 It is still unknown if the amenorrhoea/menstrual dysfunction
which occurred in 23% of the menstruating patients treated with
phenylbutyrate as reported by Wiech et al. [14] was due to this drug
or to other causes like inadequate protein supply.
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Discussion
The progress made in the treatment of UCDs has clearly
improved the survival of patients during the ﬁrst 2–3
years, but at the cost of more retarded patients. When
excluding neonatal presentation, the survival ﬁgures
presented here reﬂect the experience reported by others
[5, 8, 11]. The high rate of retarded children is in
accordance with the data of Maestri et al. [7] for
argininosuccinic aciduria treated mostly with phen-
ylbutyrate. The prognosis has been shown to be better in
prospectively treated newborns; these were not included
in this study [6].
UCDs are characterised by the fact that environ-
mental factors like minor infections which are inevitable
and excessive protein restriction lead to catabolism as
does an excessive protein intake (sometimes found in
puberty). Even if genotype/phenotype relationships can
be shown, the interference by environmental factors is
such in UCD that a high uncertainty for prognosis
remains. These factors are often unpredictable and, in
contrast to PKU, lead to major crises and irreversible
damage.
With the current schedule of blood sampling for
neonatal screening on the 3rd or 4th day of life, more
than 50% of the symptomatic patients would be missed.
Since at that age the mean ammonia level greatly exceeds
300 lmol/l in symptomatic patients, these will most
likely be retarded [2, 13].
Prolongation of life as such is not a goal of medicine.
Many parents, families and patients suﬀer from restric-
tions imposed by the stringent diet, the dependency of a
metabolic centre for monitoring, the recurrent anxiety
Fig. 1 Survival curve (Kaplan-
Meier) of patients with new
therapy (lines) compared to old
therapy (dotted lines). The outer
thinner lines are the
corresponding 95% conﬁdence
limits
Fig. 2 Age at which the ﬁrst symptoms were observed, shown
according to diagnosis. (AL argininosuccinate lyase deﬁciency
(argininosuccinic aciduria), ARG arginase 1 deﬁciency (arginina-
emia), AS argininosuccinate synthetase deﬁciency (citrullinaemia
type 1), CPS carbamoylphosphate synthetase deﬁciency, OTCm
and OTCf ornithine transcarbamylase deﬁciency (male and
female). Other: lysinuric protein intolerance, hyperammonaemia-
hyperornithinaemia-homocitrullinuria syndrome, N-acetylgluta-
mate synthetase deﬁciency, and transient hyperammonaemia of
the premature newborn)
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raised by crises, the many hospitalisations and especially
from the disabilities of the patients. Since the present
treatment appears not to be eﬀective on long term, a
population screening for UCD is, in our opinion, not
indicated at present. The absence of a suﬃciently dense
referral organisation (not limited to a few major tertiary
hospitals) with competent regional specialised centres
for rapid work-up and diagnosis and metabolic crisis
management, tight control of treatment and support to
the parents is one of the major additional arguments
against neonatal screening. One should be aware that a
long delay in conﬁrming (or excluding) the diagnosis
contributes to the vulnerable child syndrome (‘‘PKU
anxiety syndrome) [12].
If a network of eﬃcient diagnostic competence cen-
tres is installed and if the resources needed for treatment,
parent support and counselling are guaranteed on a
long-term basis, it can well be argued that even with a
bad prognosis and absence of proven eﬀective treatment,
the oﬀer of a tentative diagnosis can be a major beneﬁt
even if it is decided not to treat; knowing the cause of
death of a child renders this tragedy more acceptable to
a family and allows genetic counselling and prospective
treatment if chosen by the parents. Such arguments
would have to be included in the prenatal information
and explained to the parents to allow them to refuse
screening if this is not acceptable to them.
Technical problems still exist for the early detection of
all UCDs or hyperammonaemic disorders. The sensitivity
and speciﬁcity (tolerable false-positive rate) and choice of
metabolite panel (e.g. high and low citrulline, arginine,
lysine, alanine, orotate) is not clear. Prior to starting pilot
studies, data are needed for comparing the plasma with
red cell concentration of these metabolites under patho-
logical conditions (at equilibrium in view of the highly
variable haematocrit in newborns) and on the inﬂuence of
the time of sampling after the end of the last feeding. In
our experience, the inﬂuence of meals (amount of protein
and post-prandial time delay of sampling) on citrulline
would hamper the use of low citrulline for detecting
mitochondrial UCDs. The pre-analytical instability of
glutamine (glutamate and pyroglutamate formation) is
well known. To restrict screening to a few of the UCDs or
hyperammonaemic disorders bears the risk that neona-
tologists and paediatricians who are not aware of the
whole complex spectrum of hyperammonaemic disorders
might exclude those by falsely assuming that all have been
excluded by the ‘‘metabolic screening’’.
For those patients who develop normally, the known
complications and more predictable risks of liver trans-
plantations and chronic immunosuppressive therapy
(for the mitochondrial defects) should be weighed
against the long-term risks of the treated UCD in each
individual case. Assessing in vivo the residual activity of
the urea cycle might be of help for this risk assessment
[16].
As general knowledge about inborn errors has im-
proved since the 1980s and the importance of diagnos-
ing, installing rapidly an adequate treatment,
monitoring and adapting it to the needs of the patients
has been better recognised, further eﬀorts must be made
for continuous education (including small hospitals).
The schematic application of therapeutic recommenda-
tions bears the danger of aminoacid imbalance and
chronic catabolism by excessive supply of benzoate or
phenylbutyrate and insuﬃcient supplement of essential
aminoacids.
Conclusions
We certainly need new therapeutic approaches and, for
this, basic knowledge on the pathogenesis of irreversible
damage to the brain by hyperammonaemic conditions.
In practice, plasma ammonia (not capillary blood)
should be assayed in sick newborns much more liberally
(24 h/24 h), e.g. whenever there is a sepsis work-up and
in older patients with loss of appetite, vomiting and
neurological symptoms. Plasma and a spot urine should
be collected and the patient transferred without hesita-
tion to a close centre with experience and competence in
treating UCDs.
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